Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03786081 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
A Phase 1 study of Cervical Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 214
- Enrollment target
- 20
- Study locations
NCT03786081: Active Phase 1 study of Cervical Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
NCT03786081 is a Phase 1 study of Cervical Cancer that is active but no longer recruiting, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 214 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03786081, a Phase 1 study of Cervical Cancer, is active but no longer recruiting, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 214 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
Primary Outcome
To establish the MTD and RP2D of tisotumab vedotin in combination
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Tisotumab Vedotin
Study Locations (20)
Ohio
- University of Cincinnati Physicians Group - Cincinnati
- Cleveland Clinic - Cleveland
- Cleveland Clinic - Cleveland
- Ohio State University Wexner Medical Center - Hilliard
California
- Univ California, Irvine Medical Center - Orange
- Olive View - UCLA Research and Education Institute - Sylmar
Montana
- Billings Clinic Cancer Center - Billings
- Montana Cancer Consortium - Billings
New York
- SUNY Downstate Medical Center - Brooklyn
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Arizona Oncology Associates - Phoenix
Florida
- Baptist MD Anderson Cancer Center - Jacksonville
Georgia
- Augusta University - Augusta
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
What the registry record for NCT03786081 still lists
NCT03786081 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03786081 names 20 study sites across 14 states, led by Ohio, California, Montana.
Frequently Asked Questions
What is clinical trial NCT03786081 about?
NCT03786081 is a clinical study titled "Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer". This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of ...
What is the current status of trial NCT03786081?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 214 participants. The study started on 2019-02-27. Estimated completion is 2026-03-31.
What conditions does trial NCT03786081 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT03786081?
The interventions under investigation include: Pembrolizumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Tisotumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03786081?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03786081 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03786081's enrollment target sits among peer trials
214 45th of 144 higher than 100 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI